VICC's Mayer departing to take new role ...

Dr. Ingrid A Mayer, MD

Claim this profile

Vanderbilt University/Ingram Cancer Center

Studies Breast Cancer
Studies Breast cancer
10 reported clinical trials
30 drugs studied

Area of expertise

1Breast Cancer
Ingrid A Mayer, MD has run 9 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive
2Breast Cancer
Ingrid A Mayer, MD has run 5 trials for Breast cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Affiliated Hospitals

Image of trial facility.
Vanderbilt University/Ingram Cancer Center
Image of trial facility.
Vanderbilt University Medical Center

Clinical Trials Ingrid A Mayer, MD is currently running

Image of trial facility.

Avelumab Combinations

for Triple Negative Breast Cancer

This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). Immunotherapy with checkpoint inhibitors like avelumab require activation of the patient's immune system. This trial includes a two week induction or lead-in of medications that can stimulate the immune system. It is our hope that this induction will improve the response to immunotherapy with avelumab. One treatment, sacituzumab Govitecan, is a monoclonal antibody called sacituzumab linked to a chemotherapy drug called SN-38. Sacituzumab govitecan is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of tumor cells, known as Tumor-associated calcium signal transducer 2 (TROP2) receptors, and delivers SN-38 to kill them. Another treatment, liposomal doxorubicin, is a form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin, and may enhance factors associated with immune response. The third medication is called binimetinib, which may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may help activate the immune system. It is not yet known whether giving avelumab in combination with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan will work better in treating patients with triple negative breast cancer.
Recruiting1 award Phase 211 criteria
Image of trial facility.

Personalized Adaptive Novel Agents

for Breast Cancer

This trial is testing new medicines along with regular cancer treatment to find the best combinations for breast cancer patients. It focuses on identifying which treatments work best based on specific cancer characteristics. Early signs of success are monitored using MRI scans and tests on blood and tissue samples.
Recruiting1 award Phase 216 criteria

More about Ingrid A Mayer, MD

Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Ingrid A Mayer, MD has experience with
  • Palbociclib
  • Sacituzumab Govitecan
  • Avelumab
  • BYL719
  • Letrozole
  • Ribociclib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Ingrid A Mayer, MD specialize in?
Is Ingrid A Mayer, MD currently recruiting for clinical trials?
Are there any treatments that Ingrid A Mayer, MD has studied deeply?
What is the best way to schedule an appointment with Ingrid A Mayer, MD?
What is the office address of Ingrid A Mayer, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security